VIM0423
Phase 2Small molecule
VIM0423 is one of 16 small molecule programs targeting Dystonia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in Dystonia
#DrugCompanyPhaseTrials
1BOTULINUM TOXIN TYPE B
EisaiApproved
Xeomin
MMerz Therapeutics GmbH
Approved
Dysport
IpsenPhase 3
Keppra
UCBPhase 2
Austedo
TevaPhase 2
Zonegran
Mylan Pharmaceuticals IncPhase 3
Neuronox
MMedy-Tox
Phase 3
Penbritin-S
Bristol-Myers SquibbPhase 1
T2000
Sun Pharmaceutical Industries, Inc.Phase 2
Incobotulinumtoxin a
UUniversity of Utah
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VIM0423. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- VVima Therapeutics